Paclitaxel (Paclitaxel) Patent Expiration, LOE Window & CMS Spending

Paclitaxel (Paclitaxel) by Daiichi Sankyo: Off-Patent Genericized (AB Competition), 4 AB generics, $7.5M 2024 CMS Part D & Medicaid spend, and $1,422 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDaiichi Sankyo
FDA Application & PathwayN211875 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$7.5M
2024 Medicare Part D Spend$204K
2024 Medicaid Spend$7.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,422 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.